Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. more
Time Frame | MREO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 8.15% | -1.8% | -0.77% |
1-Month Return | -10.05% | -3.48% | 0.71% |
3-Month Return | -17.38% | -7.2% | 8.81% |
6-Month Return | 9.38% | -1.54% | 12.32% |
1-Year Return | 93.47% | 8.39% | 30.57% |
3-Year Return | 134.76% | 6.07% | 29.21% |
5-Year Return | 126.87% | 44.07% | 91.95% |
10-Year Return | -40.77% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | (122.00K) | 393.00K | 36.46M | 1.51M | 10.00M | [{"date":"2019-12-31","value":-0.33,"profit":false},{"date":"2020-12-31","value":1.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.13,"profit":true},{"date":"2023-12-31","value":27.42,"profit":true}] |
Cost of Revenue | 23.61M | 16.35M | 17.91M | 936.00K | 2.57M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":69.24,"profit":true},{"date":"2021-12-31","value":75.86,"profit":true},{"date":"2022-12-31","value":3.96,"profit":true},{"date":"2023-12-31","value":10.9,"profit":true}] |
Gross Profit | (23.73M) | (15.95M) | 18.56M | 571.00K | 7.43M | [{"date":"2019-12-31","value":-127.88,"profit":false},{"date":"2020-12-31","value":-85.98,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.08,"profit":true},{"date":"2023-12-31","value":40.02,"profit":true}] |
Gross Margin | 19450.82% | (4059.54%) | 50.89% | 37.89% | 74.26% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-20.87,"profit":false},{"date":"2021-12-31","value":0.26,"profit":true},{"date":"2022-12-31","value":0.19,"profit":true},{"date":"2023-12-31","value":0.38,"profit":true}] |
Operating Expenses | 15.91M | 21.22M | 39.49M | 44.51M | 35.84M | [{"date":"2019-12-31","value":35.75,"profit":true},{"date":"2020-12-31","value":47.68,"profit":true},{"date":"2021-12-31","value":88.74,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.53,"profit":true}] |
Operating Income | (39.52M) | (37.57M) | (20.94M) | (43.57M) | (28.42M) | [{"date":"2019-12-31","value":-3951700000,"profit":false},{"date":"2020-12-31","value":-3756900000,"profit":false},{"date":"2021-12-31","value":-2093600000,"profit":false},{"date":"2022-12-31","value":-4356900000,"profit":false},{"date":"2023-12-31","value":-2841600000,"profit":false}] |
Total Non-Operating Income/Expense | (5.18M) | (135.61M) | 36.14M | 4.81M | (2.33M) | [{"date":"2019-12-31","value":-14.32,"profit":false},{"date":"2020-12-31","value":-375.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":13.31,"profit":true},{"date":"2023-12-31","value":-6.45,"profit":false}] |
Pre-Tax Income | (41.12M) | (166.45M) | 14.24M | (36.09M) | (30.00M) | [{"date":"2019-12-31","value":-288.73,"profit":false},{"date":"2020-12-31","value":-1168.81,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-253.44,"profit":false},{"date":"2023-12-31","value":-210.65,"profit":false}] |
Income Taxes | (6.27M) | (2.82M) | 1.52M | (1.90M) | (532.00K) | [{"date":"2019-12-31","value":-413.85,"profit":false},{"date":"2020-12-31","value":-186.15,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-125.13,"profit":false},{"date":"2023-12-31","value":-35.09,"profit":false}] |
Income After Taxes | (34.84M) | (163.63M) | 12.72M | (34.20M) | (29.47M) | [{"date":"2019-12-31","value":-273.82,"profit":false},{"date":"2020-12-31","value":-1285.88,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-268.73,"profit":false},{"date":"2023-12-31","value":-231.56,"profit":false}] |
Income From Continuous Operations | (34.84M) | (163.63M) | 12.72M | (34.20M) | (29.47M) | [{"date":"2019-12-31","value":-273.82,"profit":false},{"date":"2020-12-31","value":-1285.88,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-268.73,"profit":false},{"date":"2023-12-31","value":-231.56,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (34.84M) | (163.63M) | 12.72M | (34.20M) | (29.47M) | [{"date":"2019-12-31","value":-273.82,"profit":false},{"date":"2020-12-31","value":-1285.88,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-268.73,"profit":false},{"date":"2023-12-31","value":-231.56,"profit":false}] |
EPS (Diluted) | (5.12) | (3.66) | - | (0.16) | - | [{"date":"2019-12-31","value":-511.79,"profit":false},{"date":"2020-12-31","value":-365.63,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-15.93,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
MREO | |
---|---|
Cash Ratio | 5.67 |
Current Ratio | 6.10 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MREO | |
---|---|
ROA (LTM) | -23.86% |
ROE (LTM) | -48.47% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MREO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.18 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.82 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MREO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 598.86 |
P/B | 8.13 |
Price/FCF | NM |
EV/R | 515.71 |
EV/Ebitda | NM |
Mereo BioPharma Group PLC ADR (MREO) share price today is $3.85
Yes, Indians can buy shares of Mereo BioPharma Group PLC ADR (MREO) on Vested. To buy Mereo BioPharma Group PLC ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MREO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mereo BioPharma Group PLC ADR (MREO) via the Vested app. You can start investing in Mereo BioPharma Group PLC ADR (MREO) with a minimum investment of $1.
You can invest in shares of Mereo BioPharma Group PLC ADR (MREO) via Vested in three simple steps:
The 52-week high price of Mereo BioPharma Group PLC ADR (MREO) is $5.02. The 52-week low price of Mereo BioPharma Group PLC ADR (MREO) is $1.97.
The price-to-earnings (P/E) ratio of Mereo BioPharma Group PLC ADR (MREO) is
The price-to-book (P/B) ratio of Mereo BioPharma Group PLC ADR (MREO) is 8.13
The dividend yield of Mereo BioPharma Group PLC ADR (MREO) is 0.00%
The market capitalization of Mereo BioPharma Group PLC ADR (MREO) is $630.80M
The stock symbol (or ticker) of Mereo BioPharma Group PLC ADR is MREO